Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome.
BACKGROUND
Dopaminergic drugs are the mainstay of treatment for restless legs syndrome (RLS). We analyzed the frequency and clinical characteristics of impulse control disorders (ICD) in patients with RLS on transdermal rotigotine treatment.


METHODS
Retrospective case series at a university movement disorder clinic (n = 28, 17 women). Symptoms of ICD were assessed via detailed history taking and scoring with the Zurich Screening Questionnaire for ICD (ZICD) prior to and after initiation of treatment.


RESULTS
None of the patients had a history of ICD prior to treatment. Baseline mean scores for patients who did (8.0 ± 2.5) and did not (6.2 ± 2.7) develop ICD under treatment did not differ. Six male patients (21%) developed various symptoms of ICD (mean ZICD scores 20.7 ± 10.2) on rotigotine treatment (mean dose: 3.8 mg/d), including binge eating, hypersexuality, compulsive shopping, pathological gambling, and punding, equaling a prevalence rate of 21%. Also in the non-ICD group, ZICD scores increased (7.5 ± 2.8).


CONCLUSIONS
This is the first report of ICD in patients treated with transdermal rotigotine for RLS. In contrast to literature, even low doses of rotigotine (mean 3.8 mg/d) can cause ICD. Therefore every prescribing physician should be aware that ICD may emerge in both RLS and PD patients on any dopaminergic treatment, and should actively ask for such symptoms. The ZICD questionnaire not only replicated the findings of detailed history taking but also showed an increased tendency towards impulsive behaviour in subjects that did not develop ICD.
Department of Neurology, UniversitätsSpital Zurich, Frauenklinikstr.26, 8091 Zurich, Switzerland. sebastian.schreglmann@usz.ch
S R
SR
Schreglmann
A R
AR
Gantenbein
G
G
Eisele
C R
CR
Baumann
D000279:Administration, Cutaneous; D000368:Aged; D000369:Aged, 80 and over; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012148:Restless Legs Syndrome / Q000150:complications / Q000175:diagnosis*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000009:adverse effects*; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects*
D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine